Brief: Monarch Therapeutics and SNAP Biosciences Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
28/05/2025 15:12
May 28 (Reuters) - Coeptis Therapeutics Holdings Inc COEP.O: MONARCH THERAPEUTICS AND SNAP BIOSCIENCES, INC., A SUBSIDIARY OF COEPTIS THERAPEUTICS HOLDINGS INC., ENTER LICENSING AGREEMENT TO BOLSTER SNAP-CAR NK CELL THERAPY IN ONCOLOGY COEPTIS THERAPEUTICS HOLDINGS INC - MONARCH TO RECEIVE UPFRONT PAYMENT, MILESTONE PAYMENTS, AND ROYALTIES Source text: ID:nGNX9W0LL5 Further company coverage: COEP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Z Squared (Delaware)
See all newsBrief: Z Squared Inc. Signs Definitive Agreement To Acquire 100% Of Paradox Data And Its Union County Campus
Brief: Z Squared, Inc. To Acquire Majority Interest In Paradox Data And Its Union County Campus, A Next-Generation Data Center Development Targeting Up To 150 MW Of Firm Power
Brief: Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement To Support Ai Infrastructure Buildout
Brief: Z Squared Appoints Jon Najarian, Pete Najarian, Marc Lopresti And Jay Zapata To Newly Formed Advisory Board
Brief: Z Squared Announces Executive Leadership Appointments To Advance Ai Infrastructure Strategy